Summit Therapeutics Inc.

Summit Therapeutics Inc.

SMMTยทNASDAQ

$15.07

+1.4%
HealthcareBiotechnology

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$11.68B
EPS-1.4400
P/E Ratio-12.11
Earnings Date08/10/2026

No Dividend Yield Data

SMMT has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

SMMT has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

SMMT has not reported any net dividends paid values in the available annual periods.

Summit Therapeutics Inc.

Summit Therapeutics Inc. Dividend History

SMMT ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

SMMT Dividend Payment History

SMMT ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
smmt

Summit Therapeutics Inc. Payout Ratio Analysis

SMMT ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-1.08B
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.